BOSTON, Oct. 16, 2015 /PRNewswire/ -- Ideal Implant Incorporated announced that the five-year clinical study results for the IDEAL IMPLANT® Structured Breast Implant will be presented at the Hot Topics in Plastic Surgery symposium during the annual meeting of the American Society of Plastic Surgeons (ASPS).
Presentation: Breast Implant Update–New Technology in Breast Prostheses
Date: October 16, 2015
Time: 11 a.m.- 4 p.m.
Location: Boston Convention and Exhibition Center; Boston, MA
The clinical trial results will be presented by Larry S. Nichter, MD, Voluntary Clinical Professor of Plastic Surgery at University of Southern California and University of California, Irvine and Immediate Past Chairman of the Department of Plastic Surgery at Hoag Memorial Hospital in Newport Beach, California. Dr. Nichter will report five-year clinical study data showing very high patient satisfaction with the outcome among 445 women at five-year post-operative visits. Patient satisfaction for those who received the IDEAL IMPLANT as their first implants was 91.9%, while satisfaction among women who received the IDEAL IMPLANT as replacements for their existing silicone gel or original saline implants was slightly higher at 92.9%.
"New products should provide meaningful benefits for patients, and the IDEAL IMPLANT satisfies an unmet need in the breast implant marketplace," said Dr. Nichter. "While the silicone gel and original saline implants each have desirable features that women like, they also have characteristics that concern women. The IDEAL IMPLANT is a new type of breast implant that combines the desirable features of the silicone gel and original saline implants, providing women the natural feel they want, coupled with only saline inside for their peace of mind."
Additional highlights of the five-year clinical results include:
- Higher follow-up rate than any previous FDA breast implant clinical trial, so the clinical data is significant and meaningful.
- Surgeon satisfaction with the outcome was high (93.9% for primary implants and 91.7% for replacement implants).
- Of the 399 women who received the IDEAL IMPLANT as their first implants, the rate of capsular contracture was 5.7%, compared to nearly double (8.8%-14.8%) for original saline and silicone gel implants from other manufacturers.
- Of the 103 women who received the IDEAL IMPLANT as a replacement for existing silicone gel or original saline implants, the rate of capsular contracture was 10.4%, compared to nearly double (7.9%-22.1%) for silicone gel implants from other manufacturers.
ABOUT IDEAL IMPLANT
The IDEAL IMPLANT is a structured breast implant made from the same safe and proven breast implant materials and manufacturing processes as other breast implants. It contains no silicone gel or new materials and has a natural feel because of its unique design. It is made entirely in the United States at an FDA-inspected manufacturing facility. And because the design is patented, no other breast implant company can manufacture or sell the IDEAL IMPLANT. The IDEAL IMPLANT is only available through a limited network of board certified or board-eligible plastic surgeons.
Refer to the FDA-approved IDEAL IMPLANT Patient Information Booklet at idealimplant.com for information about the risks and benefits associated with the IDEAL IMPLANT® Structured Breast Implant. Additional information may be obtained at idealimplant.com.
Contact: IDEAL IMPLANT, 917-633-4380, [email protected]
SOURCE Ideal Implant Incorporated